Cryoballoon atrial fibrillation ablation: Single-center safety and efficacy data using a novel cryoballoon technology compared to a historical balloon platform

J Cardiovasc Electrophysiol

12 Febbraio Feb 2021 2 months ago
  • Kochi AN, Moltrasio M, Tundo F, Riva S, Ascione C, Dessanai MA, Pizzamiglio F, Vettor G, Cellucci S, Gasperetti A, Tondo C, Fassini G.

Catheter ablation is superior to drugs regarding atrial fibrillation (AF) recurrence, symptoms improvement, and mortality reduction in heart failure. POLARx™ is a novel cryoballoon, with technical improvements seeking to improve outcomes. So far, its clinical evidence is restricted to a case report.

Reference

Kochi AN, Moltrasio M, Tundo F, Riva S, Ascione C, Dessanai MA, Pizzamiglio F, Vettor G, Cellucci S, Gasperetti A, Tondo C, Fassini G. Cryoballoon atrial fibrillation ablation: Single-center safety and efficacy data using a novel cryoballoon technology compared to a historical balloon platform. J Cardiovasc Electrophysiol 2021 Feb 3. doi: 10.1111/jce.14930

Go to PubMed